Tirzapic 20mg/3ml 1 Pen by Pharmacona

Usage

1. Remove Tirzapic from the refrigerator 30 minutes before injection to allow the solution to reach room temperature — cold solution increases injection discomfort and can impair dial mechanism function.
2. Inspect the pen window: the solution should be clear and colourless; discard if particulate matter or discolouration is visible, as this may indicate compromised GLP-1/GIP receptor-active peptide integrity.
3. Attach a new sterile pen needle, then prime the pen by dialling the smallest dose increment and ejecting until a drop appears at the needle tip — this removes air that could interrupt accurate dual-agonist delivery.
4. Select the prescribed dose using the dial; choose a subcutaneous injection site — lower abdomen (at least 5 cm from the navel), outer thigh, or upper arm — and rotate sites each week to prevent lipohypertrophy, which impairs peptide absorption kinetics.
5. Insert the needle fully at a 90-degree angle, press the injection button completely, and maintain pressure for a full ten-second count before withdrawing — this ensures the entire tirzepatide dose is deposited subcutaneously rather than tracked back along the needle channel.
6. Dispose of the used needle immediately in a sharps container; recap the pen without a needle attached and record the injection date — once-weekly consistency is critical to maintaining stable plasma tirzepatide concentrations and uninterrupted GIP/GLP-1 receptor occupancy.

Warnings

Frequently asked questions

How does dual GLP-1 and GIP receptor activation produce greater weight loss than GLP-1 alone?

Activating both receptors simultaneously creates complementary metabolic signals: GLP-1 agonism slows gastric emptying and reduces glucagon, while GIP agonism improves adipose insulin sensitivity and reinforces hypothalamic satiety signalling. SURPASS Phase 3 data showed tirzepatide achieving 3–5 % additional mean body-weight reduction compared to GLP-1 mono-agonists at matched dose durations, attributing the difference to the additive GIP pathway contribution.

What is the structural difference between a GLP-1 agonist and a GIP agonist in terms of receptor binding?

GLP-1 receptor agonists mimic the native incretin GLP-1, binding its specific G-protein-coupled receptor to stimulate insulin secretion and inhibit glucagon. GIP agonists target a separate receptor (GIPR) expressed on adipocytes, pancreatic beta-cells, and central neurons. Tirzepatide is engineered as a single peptide molecule with structural motifs that engage both receptors — something natural GLP-1 or GIP cannot do individually.

Why does tirzepatide slow gastric emptying, and what effect does this have on caloric intake?

Tirzepatide slows gastric emptying by activating GLP-1 receptors on vagal afferent nerve endings, suppressing the enteric motility reflex and extending nutrient retention time in the stomach. This delays glucose absorption, flattens postprandial insulin spikes, and prolongs the mechanical sensation of fullness — collectively reducing voluntary caloric intake without requiring conscious dietary restriction.

How do I dial and administer a dose from the Tirzapic prefilled pen?

Remove the pen cap, attach a fresh needle, and prime with a small dose per the manufacturer's instructions. Dial your prescribed dose using the dose selector — each click corresponds to a defined increment. Inject subcutaneously into the abdomen, thigh, or upper arm, inserting the needle at a 90-degree angle. Hold for a full count of ten before withdrawing, then dispose of the needle safely. Never share pens.

What is the correct storage protocol for Tirzapic, and how long is the pen usable after first use?

Store Tirzapic pens refrigerated at 2–8 °C until first use; do not freeze. Once the pen has been used for the first time, it may be kept at room temperature (below 30 °C) for up to 21 days. Keep the pen away from direct light and heat. Always record the date of first use on the pen label and discard after the approved in-use period regardless of remaining volume. (2) angle_used

Manufacturer

Tirzapic occupies a distinct position within Pharmacona's injectable peptide portfolio: it is the company's first dual-receptor incretin compound — targeting both GLP-1 and GIP pathways — as opposed to the mono-agonist semaglutide-based products the brand introduced earlier. Pharmacona's decision to develop Tirzapic in a 20 mg/3 ml prefilled-pen format reflects an engineering commitment to accommodating the full tirzepatide titration range within a single pen volume, avoiding the dose-limitation constraints of lower-fill alternatives. The company's background in high-specificity peptide synthesis underpins this: tirzepatide's bifunctional molecular architecture demands tighter process controls during synthesis and fill-finish than a single-target incretin, and Pharmacona's GMP-certified production environment is structured to meet those elevated requirements. Batch release for Tirzapic follows a two-criterion protocol — HPLC quantification to verify that the declared 20 mg tirzepatide per pen is present at the correct potency, and LAL (Limulus Amebocyte Lysate) endotoxin testing to confirm parenteral safety — with a batch-specific Certificate of Analysis made available to verified purchasers upon request.